Search - tctmd.com

Displaying 261 - 280 of 422

Sort: Relevancy | Date

News Conference News EAS 2019

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

Michael O'Riordan

June 04, 2019

News Conference News EAS 2019

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

Michael O'Riordan

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Michael O'Riordan

May 20, 2019

News Daily News

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

Michael O'Riordan

May 15, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Michael O'Riordan

April 22, 2019

News Daily News

Patients Stop CVD Medications When Their Pharmacy Closes

Michael O'Riordan

April 19, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

News Daily News

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

L.A. McKeown

April 03, 2019

News Daily News

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Michael O'Riordan

March 27, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Daily News

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Michael O'Riordan

March 15, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

Quality of CAD Care Varies by Type of Medicare Coverage

Todd Neale

February 20, 2019

News Daily News

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

Lucy Hicks

February 15, 2019

News Daily News

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Shelley Wood

February 12, 2019

Advertisement

Inclisiran Safe and Effective in Patients With Impaired Renal Function: ORION

FH Patients Derive Biggest Absolute Benefit From Statin Therapy: 4S Analysis

CHD Mortality Significantly Elevated in Patients With Severe FH

Higher Risk of Intracranial Hemorrhage With Aspirin in Primary Prevention

Familial Hypercholesterolemia Seen in 10% of Young MI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

No Need for Niacin? Meta-analysis Argues the End Is Nigh

EXCEL Insights: CABG Outcomes for Left Main CAD Have Improved Substantially

Patients Stop CVD Medications When Their Pharmacy Closes

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Color-Coded Cues and Physician Prompts Boost Evidence-Based Therapy in High-Risk CVD

Many Statin-Eligible Patients Don’t Take Meds, and Say Doctor Is to Blame

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Bempedoic Acid Boosts LDL Cholesterol-Lowering in Statin-Treated CVD Patients: CLEAR Harmony

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Quality of CAD Care Varies by Type of Medicare Coverage

Lower Statin Adherence Linked to Higher Mortality Risk, Even Among Patients With Established ASCVD

Alirocumab Price Cut Makes Second PCSK9 Inhibitor More Affordable

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content